NCT06668584View on ClinicalTrials.gov

A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies

PHASE2RecruitingINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions

Myeloid Malignancies

Interventions

DRUG

Olutasidenib

Given by mouth

Trial Locations (1)

77030

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER